17th Annual Outsourcing in Clinical Trials Europe 2027

Creating a collaborative environment where pharma & biotech leaders can find solutions to current challenges through innovations and partnerships

27 - 28

April

2027

Hyatt Regency Barcelona Tower, Barcelona, Spain
Complimentary

Back

Ken Getz

Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Ken Getz is the Executive Director and a research professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, where he conducts grant-funded research on pharmaceutical R&D management and execution; protocol design optimization; contract service provider and investigative site management; e-clinical technology and data usage; and patient and community engagement. He is also the chairman of CISCRP – a nonprofit internationally-recognized organization that he founded to educate and raise public and patient awareness of the clinical research enterprise. And the president of the Otsuka Patient Assistance Foundation. A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-review journals, books and in the trade press and writes a bi-monthly column nominated for a Neal Award in Applied Clinical Trials. He holds a number of board appointments in the private and public sectors and serves on the editorial boards of Pharmaceutical Medicine, Life Science Leader and Therapeutic Innovation and Regulatory Science. Ken received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree, Phi Beta Kappa, from Brandeis University. He is the founder of CenterWatch, a leading publisher in the clinical trials industry, and one of several businesses that he has created and sold.

Next speaker

Back

Bernhard Glombitza

PhD, Vice President, Head of Clinical Operations & Customer Engagement, EMEA & LATM, Bayer

Dr Bernhard Glombitza, a senior leader in Clinical Operations has evolved through progressively increasing responsibilities in project and people management, beginning as a project leader in R&D and culminating in roles as Head of Clinical Operations for EMEA, APAC, and LATAM. He played a pivotal role in the successful launch of the Xarelto project, managing an interdisciplinary team of over 500 global employees, which significantly contributed to its market approval and commercial success. Transitioning into Clinical Operations, he leads large organizations with up to 1000 FTEs across 40 countries, achieving > 25% increase in productivity through innovative resource management and organizational restructuring. Currently, he is introducing the Dynamic Shared Ownership model in Clinical Operations, empowering decentralized decision-making and optimizing talent allocation to drive impactful results.

Next speaker

Back

Emma Blasi Bosch

Director, Global Regulatory Strategy, Alexion Pharmaceuticals

Emma has over 18 years of experience in the biopharmaceutical industry, spanning biotech startups, multinational companies and consultancy. She specializes in developing and implementing global regulatory strategies and successfully leading meetings with international regulatory agencies. As a global regulatory lead, she provides key insights to global programs focused on rare disease and oncology drug development, from first-in-human through late-phase clinical development and registration trials to successfully register unique, innovative, and technologically complex products.

Next speaker

Back

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

Clinical Operations professional leader with 18+yrs experience in Clinical Drug Development from both Big Pharma & small immunoncology biotech settings. Motivated by developing medicinal products that improves patient’s quality of life. Key competencies includes but are not limited to ICH-GCP, clinical trial regulations & guidelines, Global Clinical Project Management phase 1-4, CRO outsourcing & management, Sponsor Oversight, Risk Management, Quality & Compliance, People leadership, management & mentoring. Currently leading ongoing immunoncology clinical trials in phase 1 & 2, and phase 3 planning for continued clinical development of key assets.

Next speaker

Back

Piotr Maslak

Senior Director, Head of Emerging Technologies, AstraZeneca

Piotr Maślak is Senior Director and Head of Emerging Technologies at AstraZeneca. He leads global efforts to transform clinical trials with digital platforms and AI – accelerating development and making research more patient-centric. Piotr has a track record of scaling enterprise AI strategies and driving award-winning innovation. Recognized for driving digital transformation in pharmaceutical industry, he is passionate about challenging conventions and shaping the future of clinical research.

Next speaker

Back

Kamil Sitarz, PhD, EMBA

Chief Operating Officer & Management Board Member, Ryvu Therapeutics

Kamil Sitarz is Chief Operating Officer and Management Board Member at Ryvu Therapeutics, a European clinical-stage oncology company advancing a diversified pipeline of innovative therapies. He leads corporate strategy, enterprise governance, capital planning, and cross-functional clinical development execution across a diversified oncology portfolio.

He has been instrumental in transforming Ryvu into a multi-program clinical-stage organization, embedding disciplined portfolio governance and architecting development pathways designed to enhance execution predictability in complex, high-risk oncology settings. His leadership integrates clinical strategy with capital allocation discipline, ensuring alignment across scientific ambition, regulatory positioning, operational design, and financial planning to drive sustainable enterprise value.

Under his direction, Ryvu has built and scaled a robust clinical development organization capable of delivering international Phase I/II programs across challenging hematologic indications and multi-country site networks. He has also played a key role in establishing and governing strategic clinical collaborations with leading global oncology partners, strengthening Ryvu’s development footprint and reinforcing its credibility within the international biotech ecosystem.

With a PhD in Medical Genetics and an Executive MBA, Kamil combines scientific depth with enterprise-level strategic and operational leadership to advance innovation with rigor, accountability, and long-term growth orientation.

Next speaker

Back

Company Information

ICON Biotech is a world leading healthcare intelligence and clinical research organisation, dedicated to the needs of small and mid-sized biopharma companies. We help biotech organisations meet their critical milestones and deliver data and evidence-based results to investors, large pharma partners and regulatory authorities. With over 8,000 staff working exclusively with biotech customers, we support over 500 biotech sponsors annually.

ICON Biotech advances clinical research by offering highly focused, integrated outsourced services and solutions, delivered by tailored teams and management that understand the different pressures faced by biotechs in their drive to solve today’s challenges, without losing sight of their mission to deliver life-changing innovations tomorrow. To learn more, please visit www.iconplc.com/biotech

Next Sponsor

Back

Company Information

1MED, a Specialty MedTech and combination product solutions provider, offering end-to-end development services and digital solutions to MedTech companies across Europe.

Our offerings include preclinical and regulatory support, quality management, clinical trial management, pre and post market trial support, biometrics, medical writing and digital solutions across the clinical research continuum with a cross-functional approach.

In the past 5 years 1Med has supported 500+ different medical devices with certification and shelf life extension.

Visit 1med.net for more information.

Company Website

To learn more, please visit our website - https://1med.net/

Next Sponsor

Back

Company Information

ARENSIA Exploratory Medicine, a German-based company, is a leader in “first-in-patient” Phase IB and II/Proof-of-Concept clinical trials across a wide range of disease areas. With 14 proprietary research clinics and cutting-edge Phase I infrastructure, ARENSIA accelerates the early detection of efficacy signals for new therapies at an unparalleled speed. Its streamlined, highly efficient approach reduces patient recruitment time and costs by over 50% compared to conventional trial sites, which are often overcrowded and understaffed. This exceptional performance has resulted in a 93% repeat business rate and robust growth through collaborations with top pharmaceutical companies, biotechs, and global CROs. Headquartered in Düsseldorf, ARENSIA operates with a team of 600 professionals across 8 countries.

Company Website

To learn more, please visit our website - http://www.arensia-em.com/

Next Sponsor

Back

Company Information

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 35,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

Company Website

To learn more, please visit our website - https://www.medidata.com

Next Sponsor

Back

Company Information

4G Clinical is a leader in randomization and trial supply management (RTSM) for the global life sciences industry, offering the only fully cloud-based, 100% configurable and flexible solution utilizing natural language processing (NLP) and integrated supply forecasting. 4G Clinical is headquartered in the Boston Biotech corridor of Wellesley, MA, with offices in Europe and Asia. For more information, please visit www.4gclinical.com

Company Website:http://www.4gclinical.com/

Next Sponsor

Back

Company Information

Founded in 1997, Ergomed is a full service, global Phase I-IV clinical development and trial management service partner with leading expertise in developing oncology and rare disease drugs. Our portfolio includes experience working with novel therapies, early phase development, immunotherapy, and adaptive trial designs. Ergomed embodies a patient-centric approach to recruitment and retention with access to global patients in vital geographical areas. Ergomed’s proven delivery record, expertise, and true partnership means our sponsors can trust us to deliver their oncology trials whatever the challenge. We also offer an industry-leading suite of specialist pharmacovigilance (PV) solutions under the PrimeVigilance brand.

Ergomed has supported and managed clinical development, trial management, pharmacovigilance, and medical information services for over 300 clients in more than 100 countries.

We deliver a complete solution for oncology trials of all sizes and complexity. For more information about Ergomed, please visit: www.ergomedcro.com

Company Website

To learn more, please visit our website - www.ergomedcro.com

Next Sponsor

Back

Company Information

Flex Databases platform is a secure, unified and compliant system for clinical trials. Our platform consists of 13 modules that cover every aspect of clinical trials, from project startup to pharmacovigilance. We offer both single modules and a unified solution to maintain all processes – you can cover all existing software needs with only one vendor.

Company Website

To learn more, please visit our website - www.flexdatabases.com

Next Sponsor

Back

Company Information

Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Company Website

To learn more, please visit our website - https://www.fortrea.com/

Next Sponsor

Back

Company Information

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development. With deep therapeutic and regulatory expertise and an expansive global footprint across the Asia-Pacific region, North America, and Europe, Novotech offers clients an accelerated path to bring life-changing therapies to market.

Company Website

To learn more, please visit our website - www.novotech-cro.com

Next Sponsor

Back

Company Information

Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. We work With Heart^TM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference.

Company Website

To learn more, please visit our website - https://www.parexel.com/

Next Sponsor

Back

Company Information

When it comes to transforming the clinical trials landscape, Replior does it by offering a full suite of tools designed specifically for all stakeholders but with a special focus on the patient. From an established EDC to an engaging best-in-class ePRO connected to Virtual Visits and eConsent, Trial Online Suite supports all phases of clinical trials in most therapeutical areas, collaborating tightly through trust and transparency with large pharmaceuticals to smaller biotech companies.

Company Website

To learn more, please visit our website - https://www.replior.com/

Next Sponsor

Back

Company Information

Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company’s Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,000 trials across 80 countries.

Company Website

To learn more, please visit our website - https://www.suvoda.com/

Next Sponsor

Back

Company Information

TFS HealthScience is a global Contract Research Organization (CRO) partnering with biotechnology and pharmaceutical companies throughout their entire clinical development journey. Bringing together nearly 700 professionals, we deliver tailored clinical research services in more than 40 countries. TFS supports customers with comprehensive solutions including full clinical development services, strategic and flexible resourcing. In partnership, we build solution-driven teams of experienced professionals working together for a healthier future. Our mission is to bring treatments to patients faster. For more information, please visit www.tfscro.com.

Company Website

To learn more, please visit our website - www.tfscro.com.

Next Sponsor

Back

Company Information

Putting patients first is in uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster, quality clinical trials and real-world studies by putting patients at the core of research. Through cloud-hosting in the US, Europe and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform supports any study or trial, from Clinical Phase I, II and III studies through to decentralized or virtual real-world studies. Find out how uMotif can improve your clinical research programs and real-world studies at www.umotif.com

Company Website

To learn more, please visit our website - www.umotif.com

Next Sponsor

Back

Company Information

Biorce builds AI infrastructure for clinical trials. Our platform, Aika, accelerates how pharmaceutical companies, biotechs, and CROs design and execute clinical research—reducing protocol development time by at least 50% while eliminating costly amendments that delay patient access to life-saving treatments. Built on a foundation of 1 million clinical trials, Aika delivers evidence-based recommendations with complete regulatory transparency. Every decision auditable and defensible before agencies like the FDA and EMA.

Company Website

To learn more, please visit our website - https://www.biorce.com/

Next Sponsor

Back

Company Information

Clariness is the leading expert in global patient recruitment; in its 20+ years’ experience, they have randomized 25,000 patients, across 175 indications, through its market leading patient portal ClinLife®, which is available in 50+ countries, and 35+ languages.

Company Website

To learn more, please visit our website - www.clariness.com

Next Sponsor

Back

Company Information

IQVIA delivers AI‑powered clinical technologies that simplify trial operations, improve patient and site experiences, and accelerate clinical development. Our secure, SaaS‑based platforms use healthcare‑grade AI to streamline workflows, reduce administrative burden, and enable smarter, faster decision‑making across the clinical trial lifecycle.

Company Website

To learn more, please visit our website - https://www.iqvia.com/solutions/technologies

Next Sponsor

Back

Company Information

Marken, UPS Healthcare Precision Logistics (formerly Marken, MNX & Polar Speed), the clinical and advanced therapy subsidiary of UPS Healthcare, unites expertise across healthcare and complex secure logistics to drive the success of our clients through innovation. Operating in 220+ countries and territories, our team of 4,000 experts orchestrate over 6.6M shipments annually at all temperature ranges across our harmonized air, sea and ground network. With a ready-now packaging catalog and global depot matrix, Marken overcomes the most complex and evolving industry challenges, mitigating risks to always make it happen. Marken offers a complete range of services that integrates drug supply, storage and distribution, advanced therapy, radio pharma logistics, patient-driven services, laboratory logistics, kitting solutions, and connected medical device management. By prioritizing quality and putting patients first, Marken ensures time and temperature-critical shipments reach those who need them most. We are ready. Now. Experience. Our Precision.

Company Website

To learn more, please visit our website - http://www.marken.com/

Next Sponsor

Back

Company Information

The Australian Trade and Investment Commission (Austrade) is Australia’s national trade and investment promotion agency. We facilitate trade and attract foreign direct investment into Australia. Austrade connects global businesses to Australian opportunities, helping foreign investors and buyers do business with Australia.

Austrade advisers can provide insight on Australian capability, alert you to latest products and technology from Australia and connect you with Australian companies. Austrade partners the strengths of Australian businesses with the needs of international markets. We can open the door to a world of opportunities.

In the spirit of reconciliation, we acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

Company Website

To learn more, please visit our website - austrade.gov.au

Next Sponsor

Back

Company Information

Caidya is a multi-therapeutic clinical research organization (CRO) serving innovators worldwide. Focused on delivery excellence and an elevated customer experience, Caidya offers a wide range of clinical services and vast therapeutic expertise, supporting its partners from pre-IND strategy, through clinical development to submission and post-marketing surveillance. Caidya leverages industry-leading and proprietary clinical technology to ensure trial transparency and data-driven decision-making. Formed in 2021 following the merger of leading CROs, dMed and Clinipace, Caidya has nearly 1,800 employees in 30+ countries throughout the world.

Company Website

To learn more, please visit our website - www.Caidya.com

Next Sponsor

Why attend?

Arena International are delighted to announce Outsourcing in Clinical Trials Europe will be returning to Barcelona in 2027!

For the 17^th Annual event, our flagship European clinical show will provide delegates with practical take-aways and solutions to their most current operational and outsourcing challenges in clinical trials.

This conference will bring leading industry professionals together to share knowledge, with a focus on collaboration, advancing clinical development and concentrating on Clinical Operations, Data Management, AI, Innovation, and Technology.

WHAT TO EXPECT FOR 2027?

With regulations ever changing and the innovative advancements of technology rapidly growing, this conference will address the everyday and perspective challenges faced when working within the clinical trial space. Legislations such as the CTIS review to Generative AI and leveraging our global trial footprint to accelerate clinical development, as well as building on our new and existing relationships within our industry.

This conference will bring industry professionals together to share knowledge, with a focus on collaboration, advancing clinical development and concentrating on clinical operations, innovation, technology and of course, patient centricity.

This is a unique opportunity to network and share knowledge with the region’s leading pharmaceutical firms, biotech’s and medical device companies, to discuss operationally efficient, specifically targeted clinical trials.

500+ Attendees	80+ Exhibitors	40+ Speakers
500+ Attendees	80+ Exhibitors
40+ Speakers

Testimonials

See What It's All About

Agenda

6 May 2026
7 May 2026

Expand All

Download Agenda

Streams

Stream one

Stream A: Clinical Operations and Outsourcing

Stream two

Stream B: AI & Tech Transformation

Stream three

Stream C: Biotech Strategy

11:30 AM

CASE STUDY: From Bench to Bedside: Building an End-to-End Biotech with an In-House Clinical Trial Unit

There are many aspects to moving from early research to clinical delivery under one roof. Using Ribocure as a case study, this session explores the practical realities of building clinical operations and establishing an in-house Phase II unit.

Building and scaling a clinical operations function
Talent, structure, and service provider strategy
Establishing an in-house Phase II unit: key considerations and patient recruitment

Speakers

Karin Johansson

Associate Director, Sample Management Lead, Ribocure

12 PM

The Global biotech sector: A CRO perspective Insights from global and China biotech leaders – What sets winning companies apart

Rising scientific and operational complexity is reshaping global biotech
Biotech confidence is strong despite escalating funding and R&D pressures
AI and modern trial designs are accelerating development and decision making
Operational discipline, especially protocol quality, now drives timeline performance
Integrated CRO partnerships enhance predictability across the development lifecycle

Speakers

Dr Ankita Minhas PhD

Executive Director, ICON Biotech

12:30 PM

Choosing the right CRO: key considerations for small biotech’s

Evaluating CRO capabilities and experience relevant to your specific therapeutic area and development stage
Balancing cost, quality and timelines within tight budget constraints
Negotiating contracts with flexibility to protect your biotech’s goals

Speakers

Neta Tobis

Director of Clinical Operations, BiomX

1 PM

Lunch and networking

2 PM

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

Analysing current market dynamics and funding trends shaping biotech growth in 2026
Addressing ongoing talent shortages and evolving workforce strategies
Funding and investment for biotechs in various regions of Europe: how has this shifted in 2026?
The impact of national political and economic changes on the biotech landscape in Europe

Speakers

Dr. Kate Dokukina

Head of clinical trials, Eilean Therapeutics

Michael Zörer

Head of Clinical Operations, VarmX

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

Astrid Pañeda Rodríguez

Senior Director Clinical Operations, Forge Biologics

2:45 PM

Built for Biotech: A Fit for Purpose FSP Model That Scales with Innovation

Designed for biotech: A Fit‑for‑Purpose FSP model, built with agility, to tailor to unique biotech needs
Scales with innovation: Flexible resourcing that grows with evolving pipelines, addressing clinical trial complexities in an ever-changing clinical trial and geopolitical landscape
Integrated expertise: Dedicated teams embedded as an extension of the sponsor with laser-focus on developing assets to time and quality
Enabling progress: Supporting development from early stages through commercialization

Speakers

Dawn Williams PhD

Executive Director, Head of Customer Delivery Unit, Adaptive Clinical Delivery, Fortrea

3:15 PM

The Pursuit of Success: Driving your drug from the lab to the patient

Defining what do we do well & what could be improved – EU vs US focus
Planning & preparation within clinical trials – focus on phase 2/3
Choosing the right trial designs for new inpatient studies
How to achieve successful launch by building appropriate phase 3 program

Speakers

Dr. Kate Dokukina

Head of clinical trials, Eilean Therapeutics

3:45 PM

Afternoon refreshments and networking

4:15 PM

Reframing the CRO: From Vendor to Risk-Reduction Partner

Why the oversight of CROs need an evolution

Transforming Role of the CRO: from vendor to strategic allies
Changing mindset from sponsor holds risks to sharing risk approach
Implementing the change in various types of trials

Speakers

Benjamen Varsano

Operational Strategy/Office Director, Ergomed Clinical Research

4:45 PM

Navigating the Evolving Biosimilars Landscape: Application of new FDA and EMA Guidance as illustrated with a biosimilar case study and implications for CROs

Learning from real-world case studies to accelerate biosimilar development and approval.
Understanding the EMA’s reflection paper and its role in shaping regulatory expectations.
Examining how a rapidly changing regulatory environment impacts development strategies.
Assessing the implications for CROs in supporting sponsors through this transition.

Speakers

Andreas Seidl

Chief Scientific Officer, Formycon

5:30 PM

Chairs closing remarks and Drinks Reception

11:30 AM

Great expectations and how to meet them – Implementing AI into your study

Understanding stakeholder expectations for AI in clinical research
Practical steps for integrating AI into study design and operations
Ensuring data quality, transparency, and regulatory compliance
Measuring adoption, engagement, and return on investment from AI initiatives

Speakers

Dr. Fabian Kreimendahl

Associate Director, Medical Evidence Biostatistics, Johnson & Johnson Innovation Medicine

12 PM

Executing Modern Clinical Trials Across Europe: Challenges And Opportunities

Europe has lost market share in global clinical, mainly to APAC
Europe’s lasting strengths are in science and expertise
Partnership and integration are key to success and CROs have a key role to play
The EU is acting now to restore Europe’s competitiveness
Europe’s long-term outlook may be stronger with the right changes

Speakers

Scott Davis

Vice President Clinical Services Europe, Novotech

12:30 PM

FIESDIE CHAT From Machine Insight to Manuel Review: AI for Vendor Proposals We will focus on

Building out the RFI? What you outsource, what you need, and how many site visits? AI

Extracting and standardizing key details from unstructured vendor documents
Identifying inconsistencies, omissions, or gaps within proposals
Supporting decision-making while safeguarding confidentiality and protecting intellectual property contained in submissions
Case Study

Moderator: Silvana Giro, Senior Management, Global Medical & Regulatory Affairs, Bracco Imaging

Speakers

Silvana Giro

Senior Manager, Global Medical & Regulatory Affairs, Bracco Imaging

Piotr Maslak

Senior Director, Head of Emerging Technologies, AstraZeneca

1 PM

Lunch and networking

2 PM

Superhuman Sourcing: The AI Evolution of Clinical Outsourcing

Artificial intelligence (AI) is transforming R&D procurement from a transactional function into a strategic, data-driven discipline across all industries. As the backbone of clinical business operations, vendor management processes are equally impacted, including onboarding, qualification, risk tracking, and governance. This session will explore how AI-enabled solutions are set to redefine traditional Excel-based workflows, promising efficiency, scalability, and strategic decision-making.

This session will explore:

How AI transforms R&D procurement from transactional to strategic.
New trends: Excel-based workflows are being replaced by intelligent automation.
Vendor onboarding, risk, and governance become data-driven and scalable.
Procurement shifts from cost control to value creation.

Speakers

Anca Copaescu

CEO & Founder, Clinical Maestro

2:15 PM

150 Days to Activation: What the UK’s New Trial Start-Up Standard Means for Europe

Understanding the UK’s new national start-up target and what it requires from sponsors and sites
Ambitious FPI benchmarks: 30 days for rare disease trials and 60 days for other studies
How the UK approach compares with clinical trial start-up timelines across European markets
What sponsors and sites across Europe can learn from the UK’s drive to accelerate study activation
Key enablers for faster start-up globally: streamlined processes, site capacity, and performance management

Speakers

Joanna Calvert

Senior Programme Manager, National Institute for Health and Care Research (NIHR)

2:45 PM

Who Should Own Your eClinical Systems? Sponsor vs CRO Decisions That Actually Impact Trial Success

There is no “best model” - but there are wrong ones
Sponsors owning systems ≠ control if operations sit with CROs
CRO-owned systems ≠ efficiency if oversight is weak
The real question is not ownership - it’s control of data, processes, and timelines
System ownership decisions directly impact: inspection readiness, study startup speed
Case study: SOLTI’s transition from legacy Oracle to modern SaaS
What Solti would do differently today

Speakers

Jaume Costa

Clinical Trial and Monitoring Manager, SOLTI - Cancer Research

Evgenia Michalcuk-Vrablik

Chief Growth Officer, Flex Databases

3:15 PM

Unlocking Efficiency in ClinicalTrials: Scaling eSource for Enhanced Data Management and Collaboration

It’s no longer a question whether digital transformation will happen—it is how fast we can scale it.
When innovations such as eSource/EHR-to-EDC operate at full swing, it will allow us to perform research that otherwise wouldn’t happen and to develop medicines that otherwise would never make it to the patient
Scaling up the technology opens new avenues for collaboration, involving pharmaceutical companies, hospitals, along with technology vendors and academic partners.

Speakers

Peter Casteleyn

Clinical Data Strategy Advisor, The European Institute for Innovation Through Health Data (iHD)

3:45 PM

Afternoon refreshments and networking

4:15 PM

AI-First Trials with Aika: How AI-Driven Operational Intelligence Is Changing Trial Execution

Protocol amendments, slow enrolment, and late feasibility surprises aren’t failures of science, they’re failures of execution. In this session, we’ll show how Aika, Biorce’s AI-driven clinical trials assistant, applies real-world operational evidence to trial design decisions before problems surface. The session includes a live demo of Aika, illustrating how teams can identify execution risk early and design more predictable, scalable trials.

Speakers

Maria João Marques, MSc, ACRP-CP

Senior Director for Clinical Solutions - Europe, Biorce

4:45 PM

AI & SUSTAINABILITY SPOTLIGHT: From Consent to Carbon Footprint: Leveraging AI for Sustainable Bio sample Operations and Biobanks

Automating bio sample logistics and enabling collaboration between stakeholders - sponsors, CROs, sites - through AI powered platforms with examples and discussing the role of AI in driving long term sustainability.

Speakers

Blanka Hezelova

Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK

5:30 PM

Chairs closing remarks and Drinks Reception Sponsored by XXX

8 AM

Registration and refreshments

8:45 AM

Chairperson’s opening remarks

Speakers

Revati Tatake

Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

9 AM

KEYNOTE Just how complex and inefficient are our clinical trials; and what can be done about it?

Empirical Data quantifying the magnitude of the problem
Identification of Opportunities to optimise protocol design and improve clinical trial performance
Case examples of strategies and their impact

Speakers

Ken Getz

Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

9:30 AM

Resilience by Design: A Proactive Operational Framework for Clinical Trial Management

Mapping critical risk points across the clinical trial lifecycle and identifying early operational signals before they escalate into issues
Strengthening Sponsor–CRO–site collaboration through structured communication pathways and performance monitoring frameworks
Shifting from reactive to proactive management by embedding contingency thinking throughout trial execution to safeguard timelines, data quality, and study outcomes

Speakers

Cristina Loi

Project Manager, 1MED

10 AM

PANEL DISCUSSION New strategies to drive clinical trial efficiency and complicity

Opportunities most resonating within panel member companies
Strategies and tactics to address these opportunities
Implementation challenges and how to overcome them
Areas of future focus and opportunity

Moderator: Ken Getz, Executive Director, Research Professor (PHCM), Tufts Center for the Study of Drug Development

Speakers

Ken Getz

Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Bernhard Glombitza

PhD, Vice President, Head of Clinical Operations & Customer Engagement, EMEA & LATM, Bayer

Estrella Garcia PhD

Executive Director Global Clinical Operations, Almirall

Joana Claverol Torres

Clinical Research Director, Hospital Sant Joan de Déu, SJD Pediatric Cancer Center Barcelona

Nicole Honigman

Global Study Director, AstraZeneca

10:30 AM

Winning the Proof-of-Concept Race Site and Investigator Practical Insights and Tactics on What It Takes to Succeed in Competitive Indications

The F1 racing concept applied to First-in-Patient protocols
Strategies to start a study in 6 weeks from submission to first screening
Real patient recruitment metrics

Speakers

Evgen Levenko PhD

Country Manager Ukraine, ARENSIA

11 AM

Morning refreshments and networking break

11:30 AM

Reimaging Clinical Operations: Navigating the Future of Efficiency and innovation….an outlook into the year 2050

Have you ever wondered what the future holds for clinical operations? Currently the industry is laser focused on decentralised trials, patient diversity, risk-based monitoring, real world evidence and digitalization but where, exactly, is all this going to lead? More importantly how can we prepare for what lies ahead? Based on experience, and market and business intelligence Bernhard will dare to give us a glimpse into the future by:

Exploring the challenges to come
Recommending solutions to implement now, in preparation for tomorrow

Speakers

Bernhard Glombitza

PhD, Vice President, Head of Clinical Operations & Customer Engagement, EMEA & LATM, Bayer

12 PM

Simulate to Succeed: The Next Generation of Clinical Trials

Harnessing the convergence of high-fidelity data with advanced AI is now essential for de-risking clinical trials and accelerating therapies to patients. What if the distance between a draft protocol and a validated study execution plan was reduced to a single, unified simulation?

Join Medidata’s Rob Buka for a deep dive into the future of holistic trial design and planning. Learn how advanced modeling and simulation capabilities within a central workspace can revolutionize trial operations. This session will illustrate Medidata’s strategy for optimizing protocol design, predicting trial outcomes, and achieving greater clinical and operational success in the next generation of drug development.

Speakers

Robert Buka

Senior Director, Product Management, Medidata

12:30 PM

Global Regulatory Perspectives

Gain insights from a Clinical Trials Global Regulatory Lead on navigating the evolving global regulatory landscape, from early development through to submission readiness.

Anticipating regulatory expectations and aligning strategies early in development
Integrating regulatory perspectives across Phase I–III to streamline approvals
Common challenges and proactive approaches in global filing preparation

Speakers

Emma Blasi Bosch

Director, Global Regulatory Strategy, Alexion Pharmaceuticals

1 PM

Lunch and networking

2 PM

Technology Spotlight: Strategies for Preserving Valuable Biomarkers in Blood

Addressing logistical challenges in clinical trials for blood sample processing
Implementing solutions to stabilize biomarkers at collection and simplify workflows

Speakers

Karlo Svrze

Senior Sales Manager, BD

2:15 PM

State of the Biopharmaceutical Industry: Trends and challenges impacting the industry

Current industry trends and issues
Blockbuster drugs on the patent cliff
Geopolitical and macroeconomic impact
Impact of AI on the pharmaceutical value chain

Speakers

Revati Tatake

Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

2:45 PM

Small Decisions, Big Study Consequences

This session explores the early protocol decisions that most strongly shape trial execution and the operational principles that matter most. Using real-world protocol scenarios as the anchor, it will examine how seemingly small design choices can create or prevent major downstream complexity

How the same protocol can lead teams in very different operational directions
Where small ambiguities become big execution problems
Which protocol elements deserve the closest scrutiny before build begins
How aligning design and operations early ensures readiness and reduces risk

Speakers

Jonathan Pritchard

Director Product Growth & Market Strategy, 4G Clinical

Siobhan McKenna-Power

Operations Manager, 4G Clinical

Aida Perera Sánchez

Clinical Project Manager, Grupo Solti

Małgorzata Lorek

Study Project Lead III, 4G Clinical

3:15 PM

EU Competitiveness in Clinical Research: Momentum, Constraints, and the Risk of Falling Behind

This session will cover:

What the data reveal about EU’s competitive position
EU CTR: momentum gained, limitations encountered, and unintended consequences
Beyond CTR: how IVDR and MDR are reshaping clinical research delivery
What must change for EU to remain attractive, including initiatives shaping the future EU landscape (FAST‑EU, COMBINE, EU Biotech Act)

Speakers

Anna Kobylińska

Director, Study Management, AstraZeneca

3:45 PM

Afternoon refreshments and networking

4:15 PM

Europe at a turning point: does the EU hold a busted flush or a full house?

The cards are already on the table. The question is whether Europe knows how to play them. This session explores how the EU can turn global uncertainty into a defining moment for clinical research, manufacturing and R&D leadership.

Closing the gap with the USA and China: accelerating decision timelines, unlocking translational funding and giving NCA alignment real teeth across all 27 member states.
Turning US instability into EU opportunity: how NIH cuts, FDA uncertainty and policy unpredictability are opening a window for EU-first trial strategies and how long it may stay open.
Making regulatory alignment stick: from ICH harmonization to more effective collaboration building a system where alignment is enforced, not just encouraged.

Speakers

Mesfin James

Head of Regulatory Affairs, TFS Health Science

4:45 PM

PANEL DISCUSSION Choosing the Right Outsourcing Model for Your Clinical Trial

Overview of outsourcing models: Full-Service Outsourcing (FSO), Functional Service Provider (FSP), and in-house
Pros and cons of each model and how to select the best fit for your trial
When hybrid approaches (mixing outsourcing and in-house) are more effective than fully outsourcing or keeping trials fully internal
Understanding why FSP is gaining popularity among sponsors and how it can help meet trial timelines

Speakers

Sonja Weiser

PhD, Senior Director, Clinical Operations, Insmed Germany

Eva Torres Costa

Director, Alliance Management, AstraZeneca

Sara Bueno Ortín

Associate Director of Global Procurement, Almirall

5:30 PM

Chairs closing remarks and Drinks Reception Sponsored by XXX

Streams

Stream one

Stream A: Clinical Operations and Outsourcing

Stream two

Stream B: AI & Tech Transformation

Stream three

Stream C: Biotech Strategy

4 PM

ROUNDTABLE DISCUSSIONS

RT 1: AI and Vendor Proposals: Hype or Help?
Silvana Giro, Senior Management, Global Medical & Regulatory Affairs, Bracco Imaging

RT 2: Patient Engagement Tools That Actually Work
Behtash Bahador, Senior Director, Community Engagement & Partnerships, CISCRP

RT 3: Key Takeaways of Project Optimus
Karin Nordbladh, Director, Clinical Operation, Immune Oncology, Alligator Bioscience

Speakers

Silvana Giro

Senior Manager, Global Medical & Regulatory Affairs, Bracco Imaging

Behtash Bahador

Senior Director, Community Engagement & Partnerships, CISCRP

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

9 AM

Keynote: Clinical trials in the age of AI – What you’ll discover

Discover how artificial intelligence is transforming clinical research by streamlining processes from protocol design to regulatory submission. This session explores practical AI applications for overcoming recruitment challenges, ensuring ethical implementation, and shaping the future of oncology trials.

Overcome Bottlenecks: Learn how AI breaks cycle inefficiencies in trial design and patient screening.
Accelerate Recruitment: See how AI-driven models and molecular matching reduce screening time and failures.
Implement Ethically: Understand frameworks for bias mitigation, data privacy, and regulatory compliance.
Future Trends: Explore next-decade innovations like digital twins and foundation models.

Speakers

Eslam Katab

Global Clinical Development Manager, Sandoz

9:30 AM

Reserved for Event Sponsor

10 AM

CISCRP Perceptions & Insights Case Study

What Patients and the Public Think: Insights on AI and Tech in Trials

As AI and emerging technologies reshape the clinical research landscape, understanding the perceptions and experiences of trial participants, patients, and the public is critical to building trust and improving trial success when these tools are used. Drawing on the latest CISCRP Perceptions & Insights bi-annual survey of over 12,000 respondents globally, this session explores concerns, expectations, and trial experiences on the use of AI and decentralized trial technologies. Practical approaches to the planning and use of these tools in research will also be shared, aligned with emerging patient-centric regulatory and good practice expectations.

Speakers

Behtash Bahador

Senior Director, Community Engagement & Partnerships, CISCRP

10:30 AM

Trial De-risking: Three Sources of Noise That Quietly Sink Clinical Trials

Every day of Phase III delay costs roughly $56,000, and much of the signal sponsors pay for is lost to three sources of noise that are largely within our control: patient attrition (Phase III dropouts frequently exceed 30%), measurement variance in subjective endpoints (placebo response of 20–40% is the norm in recall-based PROs), and unmeasured environmental exposure (light is still captured, if at all, by a checkbox).

This session presents a practical framework for addressing each source with measurement rather than molecules, combining behavioral-science eCOA with sensor-based digital endpoints — ScratchSense for continuous itch and sleep quantification, and RaySense for UV, visible, and infrared exposure. The framework is applicable across dermatology, pruritus-driven indications (atopic dermatitis, CKD-associated pruritus, chronic urticaria, prurigo nodularis), lupus, chronobiology, and photosensitive-drug safety programs. The session includes a live ScratchSense demonstration showing the gap between recall-based itch reporting and continuous objective measurement.

Attendees will:

Understand how attrition, endpoint variance, and environmental exposure each inflate clinical trial sample size and timelines
Learn how behavioral-science eCOA and continuous sensor-based endpoints reduce measurement noise and required sample sizes
Examine real-world retention and measurement outcomes, including a recent 28-week dermatology program with 99% retention versus an ~80% benchmark
See a live ScratchSense demonstration of continuous scratch capture versus patient-recalled itch

Speakers

Christer Nilsson

Chief Executive Officer, Replior

11 AM

Morning refreshments and networking break

11:45 AM

Flexible AI Transformation: Faster, More Reliable Site Payments Across Europe

Learn how AI can effectively power finance teams by removing repetitive taks, guiding checks, and speeding trial set‑up and operations.
Empower your team to navigate multi‑country rules, local processes and currencies more efficiently, with clearer oversight and fewer downstream payment errors.
See newly launched solutions that give trial sponsors flexible, country-level control, plus connectivity to existing systems as you scale.

Speakers

Lorenzo Parma, PhD, MBA

Director, Solution Engineering, IQVIA Technologies

12:15 PM

AI Patient Crew – A Patient-led project for Involvement in AI Tool Design

The challenge
The proposed solution
What worked well
Even better if...

Speakers

Richard Stephens

Patient Advocate and Project Leader., AI Patient Crew

12:45 PM

Reserved for Event Sponsor

1:15 PM

Lunch and networking

2:15 PM

Interactive Workshop: Overcoming Recruitment Challenges in Clinical Research

What are the biggest barriers preventing patients from enrolling in clinical trials today?
How can sites and sponsors improve recruitment strategies to reach the right patients faster?
What role can digital tools, data, and patient engagement play in accelerating enrollment?
How can collaboration between sponsors, CROs, sites, and patient communities transform recruitment outcomes?

Speakers

Astrid Pañeda Rodríguez

Senior Director Clinical Operations, Forge Biologics

2:45 PM

PANEL DISCUSSION: Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

Reimagining responsibilities across clinical trial functions in an AI- and automation-driven environment
Evolving from task-based roles to strategic, insight-driven contributors across operations and data functions
Redefining entry-level roles as technology reshapes foundational skills, expectations, and career pathways
Identifying the new capabilities required to ensure technology enhances, not replaces the expertise of clinical trial professionals

Speakers

Kamil Sitarz, PhD, EMBA

Chief Operating Officer & Management Board Member, Ryvu Therapeutics

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

Himanshu Sahu

Clinical Data Management Specialist, Nestlé Research – Nestlé Clinical Research Unit

Robert Buka

Senior Director, Product Management, Medidata

3:30 PM

Afternoon refreshments and networking with Apple Prize Draw

4 PM

WORKSHOP Training Teams to Respond to Inspection Findings — An AI-Supported Approach

Concept

Participants work through a real inspection finding scenario using an interactive training approach that combines regulatory requirements, audit observations, and AI-supported decision-making.

Takeaway: Transferable methodology for training teams to prepare for inspections using AI while maintaining audit trail and regulatory compliance.

Speakers

Maxim Bunimovich

Co Founder & CEO, GCP Auditor and Trainer, THE QARP

8 AM

Registration and Breakfast Refreshments

8:45 AM

Chairperson’s opening remarks

9 AM

CRO Governance 2.0: Lead, Align, Accelerate

Why the oversight of CROs need an evolution
Elevating the Strategic Role of the CRO: from oversight to influence
Align: integrating risks across the organization
Accelerate, enabling speed with confidence
Governance design in practice

Speakers

Eva Torres Costa

Director, Alliance Management, AstraZeneca

9:30 AM

Patient and site realities: New data and what it means for technology’s role

With the increasing complexity of clinical trials, we are seeing a heightened responsibility and burden placed on both patients and sites. In this session, we will:

Explore the latest insights on participant challenges and preferences, drawing on the latest CISCRP Perceptions & Insights Study
Share what research sites are calling out as top priorities in supporting their patients and studies
Showcase how patient- and site-centric solutions can reduce workload, enhance visibility, and streamline the clinical trial journey

Speakers

Daniela Duffett

Head of Solutions Consulting, eClinical Services, Suvoda

10 AM

CASE STUDY Pediatric Case Study: Insights for Faster, Safer Clinical Trials

Paediatric trials bring amplified risks, tighter regulations, and higher stakes for patient safety - but the lessons learned extend far beyond children’s studies. In this case study, we examine the unique challenges of conducting a paediatric clinical trial and explore how its insights can be applied to improve planning, safety oversight, and operational efficiency in any therapeutic area.

Navigating Complex Risk Profiles: Managing safety, dosing, and ethical considerations in vulnerable populations.
Pharmacovigilance in Practice: Meeting rigorous monitoring and reporting demands under high scrutiny.
Recruitment and Engagement Strategies: Overcoming barriers to participation with patients, caregivers, and advocacy groups.
Transferable Takeaways: Applying lessons from paediatric research to accelerate and safeguard trials in all therapeutic areas.

Speakers

Joana Claverol Torres

Clinical Research Director, Hospital Sant Joan de Déu, SJD Pediatric Cancer Center Barcelona

10:30 AM

Demonstrating Proof-of-Concept in 3 Days: Operational Excellence in a Selective JAK1 Inhibitor (Londamocitinib) FIH respiratory trial

Asthma is characterised by chronic airway inflammation and bronchial hyperreactivity. Despite treatment with inhaled corticosteroids and bronchodilators, a proportion of patients do not achieve adequate asthma control.
Several cytokines and growth factors involved in asthma-related inflammation interact with Janus Kinase 1 (JAK1). Londamocitinib is a potent and selective inhaled JAK1 inhibitor designed for the treatment of asthma.
In this FIH study, oral inhalation of Londamocitinib had an acceptable safety and tolerability profile in healthy volunteers and asthmatic patients.
A 50% reduction in mean FeNO was seen in asthmatic patients after 3 days, which persisted until the last dose.
This preliminary data demonstrates anti-inflammatory effects in the lungs with minimal systemic exposure of Londamocitinib, supporting the rationale for further studies to investigate the clinical efficacy of londamocitinib in patients with asthma.

Speakers

Pablo Forte Soto, MD, MSc, DPhil, FFPM

Director, Safety Human Pharmacology, Parexel EPCU London

11 AM

Morning refreshments and networking break

11:45 AM

Why are eCOA still so hard?

Despite decades of experience implementing electronic clinical outcome assessments (eCOAs) in clinical trials, we continue to grapple with the same operational challenges during set-up and implementation. They’re solvable - yet they persist. Why?

This presentation will discuss key barriers that continue to slow progress, including:

Licensing and copyright holder review processes
Perceived need for screenshots for IRB/EC submission
Fragmented stakeholder collaboration and lack of true partnership
Unbalanced expectations – electronic vs paper, BYOD vs provisioned
Missconceptions around regulatory expectations

By addressing these challenges head-on, and fostering genuine collaboration, we can solve them if we truly want to gain efficiencies and optimisations in clinical trial set-up.

Speakers

Florence Mowlem

Chief Scientific Officer, uMotif

12:15 PM

Implementing FDA’s Project Optimus in an ongoing trial – a case study

Speakers

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

12:45 PM

How Real-World Data Drives Enrollment of Undiagnosed Patient Populations

Leveraging peer-reviewed science to bridge the gaps in diagnoses to connect more patients with clinical trials

We show how Patient and Site Burden Indexing helps quantify barriers to clinical trial participation, setting the foundation for smarter recruitment strategies
How to go beyond the traditional site feasibility by combining real-world data from patient feasibility studies and patient population insights to identify and reach more patients
Real-life case studies from our peer-reviewed papers demonstrating how data-driven, tailored campaigns highlight diagnosis gaps, improve patient reach, and de-risk enrollment outcomes

Speakers

Dr Tobias Kruse

Chief Scientific Officer, Clariness

1:15 PM

Lunch and networking

2:15 PM

TECH SPOTLIGHT: End‑of‑Study Management: Ensuring Seamless Trial Closeout with Minimal Operational Burden

Full regulatory compliance supported by robust documentation and end‑to‑end traceability
Complete transparency with no hidden or unexpected costs or fees
Streamlined management designed to avoid any additional workload for study teams

Speakers

Valentin Despocq

Business Development Manager, Quipment

Grégoire Fortin

Sales Coordinator Quipment

2:30 PM

From First-in-Human to Global Trials: How Emerging Biotechs and Biopharmas Can De-Risk Clinical Development

For emerging biotechs and biopharmas, the path from early-phase trials to global development is filled with operational and strategic risk. Increasing protocol complexity, fragmented vendor landscapes, and varying regulatory expectations add layers of uncertainty. In this talk, Adam Marsh will outline key inflection points where risk can be proactively mitigated, from study design through execution and scale-up. Attendees will leave with a clearer framework for reducing execution risk while enabling faster, more confident decision-making.

Speakers

Katarzyna (Kasia) Kalisiak, PhD

Associate Director, Caidya, RBQM Solutions Department

2:45 PM

PANEL DISCUSSION Maximising Site Productivity: Reducing Burden and Strengthening Output

As clinical trial protocols grow more complex, sites are under increasing pressure, juggling high workloads, limited resources, and administrative overload. This panel will explore practical strategies to optimise site performance, while acknowledging the real constraints they face today.

We’ll examine:

The current challenges impacting site productivity
The consequences of site strain on trial delivery
Forward-thinking solutions to streamline operations and improve collaboration
Where electronic systems support, and where they still fall short

Moderator: Sonja Weiser, PhD,Senior Director, Clinical Operations, Insmed Germany

Speakers

Sonja Weiser

PhD, Senior Director, Clinical Operations, Insmed Germany

Michael Zörer

Head of Clinical Operations, VarmX

Nicole Honigman

Global Study Director, AstraZeneca

Joana Claverol Torres

Clinical Research Director, Hospital Sant Joan de Déu, SJD Pediatric Cancer Center Barcelona

3:30 PM

Afternoon refreshments and networking with Apple Prize Draw

5 PM

END OF CONFERENCE

Speakers

Select a speaker to learn more

Back

Ken Getz

Executive Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

Session Details:

PANEL DISCUSSION New strategies to drive clinical trial efficiency and complicity

2026-05-06, 10:00 AM

Session Details:

KEYNOTE Just how complex and inefficient are our clinical trials; and what can be done about it?

2026-05-06, 9:00 AM

View In Agenda

Next speaker

Back

Bernhard Glombitza

PhD, Vice President, Head of Clinical Operations & Customer Engagement, EMEA & LATM, Bayer

Session Details:

PANEL DISCUSSION New strategies to drive clinical trial efficiency and complicity

2026-05-06, 10:00 AM

Session Details:

Reimaging Clinical Operations: Navigating the Future of Efficiency and innovation….an outlook into the year 2050

2026-05-06, 11:30 AM

View In Agenda

Next speaker

Back

Dr. Fabian Kreimendahl

Associate Director, Medical Evidence Biostatistics, Johnson & Johnson Innovation Medicine

Session Details:

Great expectations and how to meet them – Implementing AI into your study

2026-05-06, 11:30 AM

View In Agenda

Next speaker

Back

Silvana Giro

Senior Manager, Global Medical & Regulatory Affairs, Bracco Imaging

Responsible for Global Outsourcing and EU Contract Management within Global Medical & Regulatory Affairs.

From 1984 to 1988 employed by Ciba-Geigy, in the Sales Marketing of chemical products, within the Customer Services.

Since 1988 employed by Bracco S.p.A. and then by Bracco Imaging S.p.A., developing different skills: Clinical Project Planning, Budget Control

Since 2000 responsible for Contract Management in Europe, including contractual negotiation for all global functions within Global Medical & Regulatory Affairs.

Since June 2002 also responsible for Global Outsourcing within Global Medical & Regulatory Affairs.

Since 2001 Silvana Giro has been invited as speaker and moderator to several conferences and seminars.

Session Details:

FIESDIE CHAT From Machine Insight to Manuel Review: AI for Vendor Proposals We will focus on

2026-05-06, 12:30 PM

Session Details:

ROUNDTABLE DISCUSSIONS

2026-05-07, 4:00 PM

View In Agenda

Next speaker

Back

Neta Tobis

Director of Clinical Operations, BiomX

Experienced Clinical Operations Director with 17 years of experience in Clinical Operations.
Establishing and managing multi-center, multi-national clinical studies across diverse therapeutic areas (including: immunology, gastroenterology, oncology, hematology, dermatology).

Session Details:

Choosing the right CRO: key considerations for small biotech’s

2026-05-06, 12:30 PM

View In Agenda

Next speaker

Back

Sonja Weiser

PhD, Senior Director, Clinical Operations, Insmed Germany

A Clinical Research Professional (Pharmacist), PhD (Medical School - Pharmacology/Toxicology) and PMP (2016) with more than 20 years’ experience in Biotech / Health Care Industry / CRO / Drug Development / Clinical Research.

Expertise ranging from Clinical Research/Clinical Operations experience in Pharma, Biotech and CRO with focus on Oncology, Immunology, Infectious Disease, Respiratory indications and Rare/Orphan indications.

Focused on goal achievement, constant striving for improving processes on an international / global level, strong project management background.

Dedication to people management as the main success factor in clinical research/clinical development – foster open & trustful communication on a global level.

Strong believer in "Manage by example" as key to success in drug development

Session Details:

PANEL DISCUSSION Choosing the Right Outsourcing Model for Your Clinical Trial

2026-05-06, 4:45 PM

Session Details:

PANEL DISCUSSION Maximising Site Productivity: Reducing Burden and Strengthening Output

2026-05-07, 2:45 PM

View In Agenda

Next speaker

Back

Peter Casteleyn

Clinical Data Strategy Advisor, The European Institute for Innovation Through Health Data (iHD)

Clinical Data Strategy Advisor @ the European Institute for Innovation through Health Data

Peter Casteleyn MSc, is a Technology Director whose mantra is enabling business to work smarter. With a career of over 24 years in the pharmaceutical industry, Peter has made significant contributions across various domains, including Commercial, Supply Chain, Development and Analytics. His work places him at the forefront of technological innovation in the field as he contributed to and triggered cross-industry collaborations in the area of bridging clinical care with clinical research.

His passion for being intellectually challenged in order to create solutions, combined with his eagerness to guide and work with teams with a positive can-do mentality in order to grow, have been key elements throughout his career.

End 2024, Peter retired from Johnson & Johnson after the successful introduction of a scalable Electronic Health Records integration capability. He firmly believes in the importance of insights from data for the health care industry supported by the interoperability of health data. He’s also a big proponent of industry wide collaboration as the key to achieve this.

Session Details:

Unlocking Efficiency in ClinicalTrials: Scaling eSource for Enhanced Data Management and Collaboration

2026-05-06, 3:15 PM

View In Agenda

Next speaker

Back

Blanka Hezelova

Associate Director, Precision Medicine Scientific Operations, Bioethics Coach, GSK

Blanka is an Associate Director within Precision Medicine Scientific Operations at GSK with over ten years of experience in research spanning from clinical site to sponsor roles, and expertise in biosample operations. She leads operational aspects of trials with a focus on innovation and excellence, successfully managing complex clinical studies while ensuring compliance and participant protection. Herf passion lies in ethical research and strategic improvements for operational efficiency.

Session Details:

AI & SUSTAINABILITY SPOTLIGHT: From Consent to Carbon Footprint: Leveraging AI for Sustainable Bio sample Operations and Biobanks

2026-05-06, 4:45 PM

View In Agenda

Next speaker

Back

Andreas Seidl

Chief Scientific Officer, Formycon

Andreas Seidl has 25 years of experience in development of biosimilars and NBEs in the biopharma industry. He is Chief Scientific Officer at Formycon AG and in this role responsible for the overall scientific strategy of the company. In the management board of the company he is accountable for pre-clinical and clinical development of the biosimilar pipeline of the company as well as drug product development, bioanalytics and IP. Before joining Formycon he was from 2019 to 2022 COO at Leukocare AG/Munich. In the managing board of Leukocare he was responsible for research & development activities, intellectual property and quality management. Until 2019 he held different local and global positions at Hexal AG, Sandoz Biopharmaceuticals and Novartis in the area of development of biopharmaceuticals. In the early days of biosimilars he coordinated the pioneering analytical and pharmaceutical development activities of the first wave of biosimilars and contributed so far to the development and approval of eleven biosimilar products. He holds a Ph.D. in the area of protein analysis and mass spectrometry from the University of Constance/Germany where he also studied chemistry.

Session Details:

Navigating the Evolving Biosimilars Landscape: Application of new FDA and EMA Guidance as illustrated with a biosimilar case study and implications for CROs

2026-05-06, 4:45 PM

View In Agenda

Next speaker

Back

Eva Torres Costa

Director, Alliance Management, AstraZeneca

Introducing Eva Torres Costa, director in global alliance management, recognized for architecting high‑impact outsourcing models and cross‑functional alignment in clinical operations and digital innovation. As Director at Alliance Manager at AstraZeneca, Eva oversees two strategic alliances for Clinical Operations (ICON and IQVIA) and serves as the final escalation point for complex business issues, and leads the COSMOS contracting schema workstream.

Previously, Eva directed R+D Clinical Outsourcing at Alexion, stewarding a $300m portfolio and a team of four, and partnering with Clinical Operations, Medical, and Data & Digital to shape category strategy and close strategic deals with our partners.

At Novartis, she was Global Category Manager for Disruptive & Digital Tech, where she led supplier relationship programs and executed major digital solution agreements.

Session Details:

PANEL DISCUSSION Choosing the Right Outsourcing Model for Your Clinical Trial

2026-05-06, 4:45 PM

Session Details:

CRO Governance 2.0: Lead, Align, Accelerate

2026-05-07, 9:00 AM

View In Agenda

Next speaker

Back

Behtash Bahador

Senior Director, Community Engagement & Partnerships, CISCRP

Behtash Bahador is the Senior Director of Community Engagement & Partnerships at the non-profit organization CISCRP, and holds a Master of Science in Health Communication from the Tufts University School of Medicine. Since 2014, he has collaborated with a range of stakeholder groups to establish and implement patient- and public-centric initiatives across the life-cycle of drug and treatment development. This has included supporting the development of regulatory and cross-disciplinary best practice guidelines, operationalizing key elements of evidence-based public health programing into research engagement activities, and always keeping the needs of patients, participants and the public at the forefront of his work.

Session Details:

CISCRP Perceptions & Insights Case Study

2026-05-07, 10:00 AM

Session Details:

ROUNDTABLE DISCUSSIONS

2026-05-07, 4:00 PM

View In Agenda

Next speaker

Back

Richard Stephens

Patient Advocate and Project Leader., AI Patient Crew

Richard has been a patient advocate for 30 years, surviving two cancers and a heart emergency, plus several co-morbidities and late effects. As a patient he has participated in four interventional studies and nine others. As an Advocate he has helped design over 30 more.

Richard Chairs the UK’s Cancer Research Advocates Forum, is Vice-Chair of the European CanSERV project, and has held several other leadership roles. He works with patient groups and advocates, academics and industry, and policy-makers, funders and regulators.

Richard helped found the AllTrials campaign and useMYdata movement, and he is the founding co-Editor-in-Chief of the Journal of Research Involvement and Engagement. His professional life included successful careers in education, journalism and local government.

Session Details:

AI Patient Crew – A Patient-led project for Involvement in AI Tool Design

2026-05-07, 12:15 PM

View In Agenda

Next speaker

Back

Revati Tatake

Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

Revati Tatake, PhD, is the Global Head of Pharma Research, Analysis and Competitive Intelligence at GlobalData Healthcare. Revati has over 25 years of multidisciplinary experience in academic research and the healthcare industry, both on the client and agency sides of the business. Previously she worked as a VP of Databases and Analytics at GlobalData, where she made significant contributions to Pharma Intelligence Center. Before joining GlobalData, Revati worked at Citeline/Informa, where she was involved in competitive intelligence and analytics of clinical trials and drugs in the areas of Autoimmune/Inflammation, Central Nervous System, and Ophthalmology. Earlier, Revati worked at Boehringer Ingelheim Pharmaceuticals for over 12 years as Senior Scientist to Senior Principal Scientist, where she led drug discovery projects involving traditional high-throughput screening, as well as innovative approaches for gene and cell therapies. She also worked at Boehringer Ingelheim as a Director of Competitive Intelligence for projects in cardiometabolic space and research beyond borders. She is a co-inventor on many issued US patents related cell and gene therapies and has several publications in peer reviewed scientific journals. Revati holds a PhD in Tumor Immunology from the Tata Cancer Research Institute in Mumbai, India. She did her postdoctoral fellowship at the University of Connecticut Health Center and Boehringer Ingelheim.

Session Details:

Chairperson’s opening remarks

2026-05-06, 8:45 AM

Session Details:

State of the Biopharmaceutical Industry: Trends and challenges impacting the industry

2026-05-06, 2:15 PM

View In Agenda

Next speaker

Back

Estrella Garcia PhD

Executive Director Global Clinical Operations, Almirall

Estrella began her ‘scientific odyssey’ at the University of Navarra, Spain, where she gained a PhD in Genetic Toxicology. Following this, Estrella held at post-doctoral position at ICI (now Astra Zeneca) in Macclesfield, UK. At ICI Estrella’s focus was on novel anti-tumor drugs in the pre-clinical phase. Subsequently Estrella returned to Spain where she joined Almirall as a Clinical Research Scientist. Since then, Estrella has amassed a 29 year career with the company- taking on roles of increasing demand and responsibility, including Head of Allergy Therapeutic Area and Head of Clinical Development Operations- to the role she holds today.

Estrella leads her group and is responsible for clinical trials worldwide. Since Almirall do not have affiliates fully involved in clinical development, the company externalizes all clinical trials, with a strategic focus on keeping only core competencies- particularly for pivotal studies- in-house. In this capacity Estrella has worked with dozens of CROs and service providers managing Phase I to Phase IV clinical trials of all sizes, from small single centre studies to global programs involving hundreds of sites and thousands of patients. Her responsibility is covering the selecting, negotiation, contracting, managing and final evaluation of the CROs responsible for the worldwide clinical development, in order to deliver on the agreed timelines, quality and cost.

She has been responsible for ensuring Clinical Development for Aclidinium bromide in COPD was performed worldwide from the operational point of view on time, budget and quality, among other development from Almirall.

Now fully focus on Dermatology development, managing trials worldwide mainly in Psoriasis, Acné, Atopic Dermatitis, Actinic Keratosis, among other indications.

Session Details:

PANEL DISCUSSION New strategies to drive clinical trial efficiency and complicity

2026-05-06, 10:00 AM

View In Agenda

Next speaker

Back

Michael Zörer

Head of Clinical Operations, VarmX

Michael is responsible for a team of 11 people and the overall delivery of the conducted studies. The group runs several studies in different indications with a clear focus on rare diseases. In 2016 AOP Orphan received approval for one new product (RAPIBLOC®). In 2019 AOP received the marketing authorization for their first biological (BESREMi®), after completing a series of clinical studies and successfully passing a series of EMA inspections under Michael’s responsibility.

Before joining AOP Orphan Michael has been operations manager for Haemophilia at Baxter. Michael has many years of experience as a project manager and learned the job in clinical research from scratch starting as CRA at Amgen. Michael received his Ph. D in biochemistry from the University of Vienna.

Session Details:

PANEL DISCUSSION Maximising Site Productivity: Reducing Burden and Strengthening Output

2026-05-07, 2:45 PM

Session Details:

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

2026-05-06, 2:00 PM

View In Agenda

Next speaker

Back

Karin Nordbladh

Director, Clinical Operation, Immune Oncology, Alligator Bioscience

Session Details:

ROUNDTABLE DISCUSSIONS

2026-05-07, 4:00 PM

Session Details:

Implementing FDA’s Project Optimus in an ongoing trial – a case study

2026-05-07, 12:15 PM

Session Details:

PANEL DISCUSSION: Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

2026-05-07, 2:45 PM

Session Details:

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

2026-05-06, 2:00 PM

View In Agenda

Next speaker

Back

Dr. Kate Dokukina

Head of clinical trials, Eilean Therapeutics

Dr. Kate Dokukina is an expert with 20+ years in the biopharmaceutical industry and medicine , specializing in clinical research, drug development, and regulatory strategy. She has led global clinical programs across oncology, autoimmune, and rare diseases, overseeing the launch of 50+ new molecules. Currently VP in clinical trials at Eilean Therapeutics(US), she has held leadership roles at BIOCAD, Shanghai Pharma and MedInvestGroup.

Session Details:

The Pursuit of Success: Driving your drug from the lab to the patient

2026-05-06, 3:15 PM

Session Details:

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

2026-05-06, 2:00 PM

View In Agenda

Next speaker

Back

Emma Blasi Bosch

Director, Global Regulatory Strategy, Alexion Pharmaceuticals

Session Details:

Global Regulatory Perspectives

2026-05-06, 12:30 PM

View In Agenda

Next speaker

Back

Piotr Maslak

Senior Director, Head of Emerging Technologies, AstraZeneca

Session Details:

FIESDIE CHAT From Machine Insight to Manuel Review: AI for Vendor Proposals We will focus on

2026-05-06, 12:30 PM

View In Agenda

Next speaker

Back

Joana Claverol Torres

Clinical Research Director, Hospital Sant Joan de Déu, SJD Pediatric Cancer Center Barcelona

Joana Claverol , is the Clinical Research Director at Barcelona Children’s Hospital Sant Joan de Déu, Spain, where she leads the clinical trials office since 2012 and the Patients engagement in research area since 2015. The Clinical Research Unit is a reference unit for pediatric patients nationally and internationally, specializing in innovative treatments for highly complex patients with rare pediatric diseases. She has more than 13 years of experience in medical and clinical research in the pharmaceutical and biotechnology industry, with special knowledge and experience in drug development and clinical trial design, and all regulatory and methodological aspects related to clinical research. She holds a postgraduate in Senior Management Program of Health Institutions by IESE Business School, a Master in Pharmaceutical Marketing by Universitat Pompeu Fabra, a Master of clinical trials at Universitat de Barcelona and a BS Degree in Biological Sciences by Universitat Autonoma de Barcelona.

Session Details:

PANEL DISCUSSION New strategies to drive clinical trial efficiency and complicity

2026-05-06, 10:00 AM

Session Details:

PANEL DISCUSSION Maximising Site Productivity: Reducing Burden and Strengthening Output

2026-05-07, 2:45 PM

Session Details:

CASE STUDY Pediatric Case Study: Insights for Faster, Safer Clinical Trials

2026-05-07, 10:00 AM

View In Agenda

Next speaker

Back

Maxim Bunimovich

Co Founder & CEO, GCP Auditor and Trainer, THE QARP

Maxim is an independent international GCP auditor and trainer with over 15 years of experience in the pharmaceutical and clinical research industry across Europe, Africa, and CIS regions. A certified MRQA and SQA expert with a medical background, he combines hands‑on audit practice with quality management expertise. He specializes in GCP audits, FDA and EMA inspection preparation (including mock inspections), and the development of Quality Management Systems (QMS) for sponsors and CROs. His practical, audit‑driven approach forms the foundation of THE QARP’s training programmes.”

I confirm the session details are fine from my side. We will share not only the presentation in 16:9 format by 24 April, but also the detailed plan for our workshop “Training Teams to Respond to Inspection Findings – An AI‑Supported Approach.

Session Details:

WORKSHOP Training Teams to Respond to Inspection Findings — An AI-Supported Approach

2026-05-07, 4:00 PM

View In Agenda

Next speaker

Back

Andrzej Szandrach

Executive Director, Head of Study Management R&I, AstraZeneca

Next speaker

Back

Jonathan Pritchard

Director Product Growth & Market Strategy, 4G Clinical

Jonathan is a seasoned leader with a proven track record in driving sales, product growth and market strategy across diverse sectors within the Clinical trials space, including Medical Devices, Biostatistics, and Contract Research Organizations (CROs). As Senior Manager, Product Growth and Market Strategy at 4G Clinical, he leverages his extensive background in sales and operations to identify and capitalize on market opportunities within the Randomization and Trial Supply Management (RTSM) space. Jonathan's strategic vision and data-driven approach are instrumental in accelerating product adoption and expanding market share, ultimately contributing to the advancement of clinical research and the development of innovative medical solutions.

Session Details:

Small Decisions, Big Study Consequences

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Dawn Williams PhD

Executive Director, Head of Customer Delivery Unit, Adaptive Clinical Delivery, Fortrea

Dawn Williams, Executive Director, based in UK. Dawn has been in clinical research for 24 years in both academic and industry setting, spending most of her career with Fortrea. During her time at Fortrea, she has specialised in FSP across multiple biopharma sponsors of varying size, from small to large partnerships, leveraging a diverse range of FSP models.

Session Details:

Built for Biotech: A Fit for Purpose FSP Model That Scales with Innovation

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Dr Ankita Minhas PhD

Executive Director, ICON Biotech

Executive Director at ICON with 15+ years of global leadership in drug development, clinical operations, and program management. Proven track record in delivering complex Phase I–III clinical trials across the USA, Europe, and Africa, with therapeutic expertise in Oncology, Vaccines, and General Medicine.

Acting Vice President and leading a multidisciplinary team of Executive and Senior Directors and Project Management professionals, driving operational excellence, strategic execution, and delivery of large-scale global portfolios.

Recognised for building strong strategic partnerships, optimizing clinical development strategies, and advancing business growth through innovation, collaboration, and disciplined execution. Committed to transforming clinical research through performance, quality, and leadership.

Session Details:

The Global biotech sector: A CRO perspective Insights from global and China biotech leaders – What sets winning companies apart

2026-05-06, 12:00 PM

View In Agenda

Next speaker

Back

Benjamen Varsano

Operational Strategy/Office Director, Ergomed Clinical Research

Dr. Varsano has 20+ years of experience in clinical research and 15+ years in leadership and oversight. He managed clinical studies for numerous rare disease indications, providing support for five approved drugs/molecules. He recently provided Project Director portfolio leadership for six rare disease Phase I-IV trials, with three of them receiving marketing authorization, one of which was a first-in-class therapy for a rare hematology condition.

20+ years of clinical research experience with 15+ years in leadership and oversight
Managed rare disease clinical studies supporting five approved drugs/molecules
Provided Project Director leadership for Phase I-IV trials, including a first-in-class rare hematology therapy

Session Details:

Reframing the CRO: From Vendor to Risk-Reduction Partner

2026-05-06, 4:15 PM

View In Agenda

Next speaker

Back

Kamil Sitarz, PhD, EMBA

Chief Operating Officer & Management Board Member, Ryvu Therapeutics

Session Details:

PANEL DISCUSSION: Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

2026-05-07, 2:45 PM

View In Agenda

Next speaker

Back

Evgen Levenko PhD

Country Manager Ukraine, ARENSIA

Evgen Levenko is a PhD in Medical Sciences, a cardiologist. His career in clinical research started over 30 years ago. He has experience in project management, planning, and oversight across more than 150 Phase I–III trials. Before joining the ARENSIA team, he worked at a number of international contract research organizations. In his current role as Country Manager, he oversees all aspects of ARENSIA’s clinical trials at the research centers across Ukraine (Kyiv and Ivano-Frankivsk clinics). Evgen is a focused and effective manager with strong leadership and professional skills. He oversaw the establishment of ARENSIA’s new research center in Kyiv, which is now ARENSIA’s largest research clinic. Under Evgen’s leadership, ARENSIA in Ukraine has become the fastest-growing branch of the international company.

Session Details:

Winning the Proof-of-Concept Race Site and Investigator Practical Insights and Tactics on What It Takes to Succeed in Competitive Indications

2026-05-06, 10:30 AM

View In Agenda

Next speaker

Back

Karin Johansson

Associate Director, Sample Management Lead, Ribocure

Karin Johansson is an Associate Director and Team Leader for Clinical Sample Management within Clinical Operations at Ribocure Pharmaceuticals. In this role, she leads the planning and execution of clinical sample strategies and oversees the scientific, operational, and regulatory aspects of sample analyses in clinical trials. She holds a Master’s degree in Pharmaceutical Bioscience from the University of Gothenburg and has extensive experience across the drug development continuum. Her background includes more than15 years of hands-on laboratory research in cardiovascular disease at AstraZeneca, as well as clinical trial operations and site-based work as a clinical research nurse at Sahlgrenska University Hospital. Karin brings a unique perspective that integrates scientific, operational, and patient-centered aspects of clinical research.

Session Details:

CASE STUDY: From Bench to Bedside: Building an End-to-End Biotech with an In-House Clinical Trial Unit

2026-05-06, 11:30 AM

View In Agenda

Next speaker

Back

Sara Bueno Ortín

Associate Director of Global Procurement, Almirall

Sara Bueno Ortín is Associate Director of Global Procurement at Almirall, where she leads R&D Procurement with a focus on clinical development, outsourcing strategy, and vendor management.

She has extensive experience negotiating complex contracts with CROs, CDMOs, and central labs, optimizing cost models, and ensuring operational excellence across global clinical programs.

Sara plays a key role in defining sourcing strategies, managing strategic suppliers, and implementing digital procurement tools to enhance efficiency and compliance.

Session Details:

PANEL DISCUSSION Choosing the Right Outsourcing Model for Your Clinical Trial

2026-05-06, 4:45 PM

View In Agenda

Next speaker

Back

Florence Mowlem

Chief Scientific Officer, uMotif

Flo is an expert eCOA scientist who has spent her career advising and guiding organizations on the electronic capture of clinical outcome assessments (COA) and the use of digital health technologies (DHTs) in clinical trials. She has a deep knowledge of clinical research, study design, and leveraging technology to support it, having worked at the intersection between science and technology to navigate for better solutions.

Flo actively participates in industry consortia, regularly publishes, and presents at international conferences. She uses her passionate and progressive mindset for driving positive change in the industry, focusing on optimising clinical trial data capture to enhance the participant and site experience.

At uMotif, she provides Scientific Leadership across the organization, ensuring that the scientific voice is embedded across all functional areas to inform rigorous scientific practices. She previously held positions at Signant Health, Medable, and ObvioHealth.

Session Details:

Why are eCOA still so hard?

2026-05-07, 11:45 AM

View In Agenda

Next speaker

Back

Himanshu Sahu

Clinical Data Management Specialist, Nestlé Research – Nestlé Clinical Research Unit

Himanshu Sahu is a Clinical Data Management Specialist at Nestle Clinical Research Unit with over 16 years of experience leading end‑to‑end clinical data management across global pharmaceutical and nutrition research. He is known for his expertise in data quality oversight, cross‑functional study leadership, and driving data‑strategy initiatives in collaboration with CROs and external service providers. A strong advocate of data storytelling, he leverages tools like Power BI to translate complex clinical data into actionable insights. His career includes key roles at Novartis, AstraZeneca, Alcon, Iqvia, and Cognizant, where he championed process optimization and innovation in data workflows. Himanshu holds an MSc in Biotechnology and a Postgraduate Certificate in Clinical Research & Data Management and is widely recognized for his strategic thinking and commitment to advancing data‑driven excellence in clinical research.

Session Details:

PANEL DISCUSSION: Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

2026-05-07, 2:45 PM

View In Agenda

Next speaker

Back

Karlo Svrze

Senior Sales Manager, BD

Karlo Svrze, MSc, FMVA® is a life‑sciences professional at BD (Becton, Dickinson & Co.) with a background spanning clinical research, diagnostics, and translational healthcare. He worked as a research scientist in regenerative medicine and biomolecular research. His current focus lies at the interface of clinical practice and diagnostics, supporting the translation of scientific and clinical requirements into robust, scalable preanalytical solutions across complex clinical trial environments.

Session Details:

Technology Spotlight: Strategies for Preserving Valuable Biomarkers in Blood

2026-05-06, 2:00 PM

View In Agenda

Next speaker

Back

Robert Buka

Senior Director, Product Management, Medidata

Robert Buka is a Senior Director for the Medidata AI Intelligent Trials portfolio. He leads the Study Feasibility product, which helps pharmaceutical sponsors and CROs use historical data and predictive algorithms to properly plan and execute their clinical trials to achieve study enrollment targets. Robert has 10 years of technology industry experience leading data science teams and delivering digital transformation projects. Robert studied Biology and Statistics at the University of Pennsylvania.

Session Details:

Simulate to Succeed: The Next Generation of Clinical Trials

2026-05-06, 12:00 PM

Session Details:

PANEL DISCUSSION: Future of Clinical Trial Professionals: How Technology Is Transforming Workforce Roles and Expectations

2026-05-07, 2:45 PM

View In Agenda

Next speaker

Back

Daniela Duffett

Head of Solutions Consulting, eClinical Services, Suvoda

Daniela leads Suvoda’s global eClinical Solutions Consulting team and is based in the Barcelona office. She works closely with clients and prospects, delivering presentations and demonstrations while serving as a subject matter expert on Suvoda’s solutions.

Daniela joined Suvoda seven years ago in the Services Delivery organization, where she worked in project management and gained deep, hands-on experience in IRT solution delivery. This background enables her to bring strong practical insight and real-world expertise to every consulting engagement.

Session Details:

Patient and site realities: New data and what it means for technology’s role

2026-05-07, 9:30 AM

View In Agenda

Next speaker

Back

Lorenzo Parma, PhD, MBA

Director, Solution Engineering, IQVIA Technologies

Lorenzo Parma is an experienced leader working at the intersection of information technology and the pharmaceutical industry. As Director of Solution Engineering at IQVIA Technologies, he brings deep expertise across clinical research and digital health, including pharmaceutics, patient data, electronic data capture (EDC), real‑world evidence (RWE), and site and patient engagement.

He is highly skilled in client engagement and solution‑driven collaboration, helping organizations translate complex data and technology into practical, impactful outcomes. Lorenzo holds a PhD in Biology and an MBA from Warwick Business School, with a focus on Marketing, Organizational Behaviour, and Coaching.

Session Details:

Flexible AI Transformation: Faster, More Reliable Site Payments Across Europe

2026-05-07, 11:45 AM

View In Agenda

Next speaker

Back

Valentin Despocq

Business Development Manager, Quipment

Session Details:

TECH SPOTLIGHT: End‑of‑Study Management: Ensuring Seamless Trial Closeout with Minimal Operational Burden

2026-05-07, 2:15 PM

View In Agenda

Next speaker

Back

Grégoire Fortin

Sales Coordinator Quipment

Session Details:

TECH SPOTLIGHT: End‑of‑Study Management: Ensuring Seamless Trial Closeout with Minimal Operational Burden

2026-05-07, 2:15 PM

View In Agenda

Next speaker

Back

Dr Tobias Kruse

Chief Scientific Officer, Clariness

He is the founder and former CEO of Trials24, a company supporting biotech and pharmaceutical companies, as well as CROs, in accelerating patient recruitment. Trials24 was acquired by SubjectWell in September 2024 prior to its merger with Clariness.

Before founding Trials24, Tobias co-founded ImevaX, a biotech company focused on vaccine development, where he developed the entire digital patient recruitment strategy.

Tobias earned his PhD in Molecular Biotechnology from the Technical University of Munich, where he developed a vaccine against Helicobacter pylori. He holds numerous patents and has published papers in journals such as Nature and EMBO.

Session Details:

How Real-World Data Drives Enrollment of Undiagnosed Patient Populations

2026-05-07, 12:45 PM

View In Agenda

Next speaker

Back

Anca Copaescu

CEO & Founder, Clinical Maestro

Anca is serial entrepreneur and currently the CEO and Founder of Clinical Maestro. As an industry leader in clinical outsourcing, she hosted multiple webinars, spoken at leading industry conferences, authored multiple articles and white papers. Anca spent more than 20 years in the pharmaceutical industry, starting with founding an antimicrobial discovery biotech, managing M&A activities in the eClinical space for top CROs, and leading clinical outsourcing, R&D finance and strategic vendor management for top biotechs. She is passionate about accelerating and lowering the costs of conducting clinical trials through efficiencies in clinical business operations by leveraging modern technology, such as Artificial Intelligence and Machine Learning.

Session Details:

Superhuman Sourcing: The AI Evolution of Clinical Outsourcing

2026-05-06, 2:00 PM

View In Agenda

Next speaker

Back

Anna Kobylińska

Director, Study Management, AstraZeneca

Clinical research leader with extensive experience in global clinical trial delivery across multiple therapeutic areas
Strong background in clinical operations, study oversight, and cross‑functional collaboration
Combines scientific expertise with expansive operational and leadership capabilities
Actively engaged in EU Clinical Trials Regulation (EU CTR) topics, with a focus on clinical research delivery and EU competitiveness
Trained pharmacist (MSc, PharmD) and Project Management Professional (PMP®)

Session Details:

EU Competitiveness in Clinical Research: Momentum, Constraints, and the Risk of Falling Behind

2026-05-06, 3:15 PM

View In Agenda

Next speaker

Back

Mesfin James

Head of Regulatory Affairs, TFS Health Science

Session Details:

Europe at a turning point: does the EU hold a busted flush or a full house?

2026-05-06, 4:15 PM

View In Agenda

Next speaker

Back

Evgenia Michalcuk-Vrablik

Chief Growth Officer, Flex Databases

Evgenia holds several degrees in International Economics and MBA in Digital Transformation, she is in top management of eSystem provider Flex Databases, one of the leading European software providers for Life Sciences.

She has been in clinical research for 15+ years, 8 years in the company management, participated in digitalization of 60+ companies 15 to 50 000 employees in the US, Europe, and Asia.

Session Details:

Who Should Own Your eClinical Systems? Sponsor vs CRO Decisions That Actually Impact Trial Success

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Astrid Pañeda Rodríguez

Senior Director Clinical Operations, Forge Biologics

Session Details:

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

2026-05-06, 2:00 PM

Session Details:

Interactive Workshop: Overcoming Recruitment Challenges in Clinical Research

2026-05-07, 2:15 PM

View In Agenda

Next speaker

Back

Joanna Calvert

Senior Programme Manager, National Institute for Health and Care Research (NIHR)

Joanna Calvert is a Senior Programme Manager within the National Institute for Health and Care Research (NIHR). Leading initiatives within in the NIHR Industry Hub, she facilitates a coordinated national system that provides a single point of entry for trial feasibility and activation. Her focus is on delivering a faster, more reliable experience for global partners, ensuring the UK operates as one of the most attractive and dependable environments for commercial research.

Session Details:

150 Days to Activation: What the UK’s New Trial Start-Up Standard Means for Europe

2026-05-06, 2:15 PM

View In Agenda

Next speaker

Back

Laura Solé Heuberger

Study Coordinator & Clinical research nurse, Sant Joan de Déu Research Foundation

Next speaker

Back

Simon Dixon

Director, Commercial Services, Sonic Clinical Trials

Simon brings more than 20 years of management and industry experience across healthcare, medical diagnostics, and clinical research, with a career spanning both commercial and not-for-profit sectors. Simon began his career with Sonic Healthcare in 1995 at Douglass Laboratories in Sydney. Over the years, Simon has held senior leadership roles at the National Heart Foundation of Australia and the NICM Health Research Institute at Western Sydney University and has also served as a Board Director for the Northern Territory AIDS and Hepatitis Council. In 2019, Simon returned to Sonic Healthcare as Director, Commercial Services at Sonic Clinical Trials. Simon studied a Bachelor of Science and a Master of Business Administration, combining scientific expertise with strong commercial acumen. He is passionate about advancing health equity and improving access to innovative treatments and medications.

Next speaker

Back

Julie Liu

CEO, Pharmsky

Next speaker

Back

Sam Vohra

Founder & CEO, Avion Full-Service CRO & Imaging Specialists

Dr Sam Vohra is the founder & CEO of Avion CRO, established in 2018 with a clear mission to provide more efficient and strategic clinical research solutions for organizations navigating the complexities of clinical trials and regulatory approvals. With a PhD in Molecular Biochemistry and a deep-rooted passion for research that began at the Royal Marsden in London, Sam brings over 20 years of experience in research and commercial launch strategy. She has led global, multi-national projects across diverse therapeutic areas, excelling in oncology and, more specifically, radiopharmaceutical trials. Her expertise spans both Australian and international markets, making her and Avion CRO a trusted leader in advancing clinical research innovation.

Next speaker

Back

David Chia

Senior Director Business Development, Nucleus Network

David is bringing over 20 years of comprehensive experience in the CRO sector, partnering with biotech, pharmaceutical, and life science organisations. Known for influencing critical business inflection drivers, developing robust clinical development strategies, and creating alignment across complex stakeholder ecosystems spanning sponsors and service providers

Next speaker

Back

Peter Wirtz

Partner, R&D Services Bentleys

Peter leads Bentleys Australia R&D services team and is responsible for delivering and managing complex R&D tax claims, defend outcomes under review and unlock funding opportunities for businesses, particularly biotech companies engaged in clinical trials.

Peter assists foreign companies set up subsidiaries in Australia, to access up to a 43.5% cash refund for eligible R&D activities.

Peter is a Chartered Accountant, with a Bachelor of Science with Honours and an MBA. Peter has over twenty years of experience in leading professional service firms and industry in China, Japan, South Africa, Brazil and Australia.

Peter has provided R&D Incentive, grants and tax advice to hundreds of clients, from start-ups to multinationals across Australia in accessing hundreds of millions of Government incentives.

In his corporate career, Peter was an executive of a fast-paced start up operating in multiple jurisdictions. As an executive Peter was responsible for R&D, and IP creation.

Next speaker

Back

Cristina Loi

Project Manager, 1MED

Cristina Loi is a deeply passionate clinical research professional with more than 5 years of experience in the management of clinical studies involving pharmaceuticals and medical devices across multiple therapeutic areas, including oncology, rare diseases, autoimmune disorders, and orthopaedics. Currently serving as Project Manager at LB Research Srl – Part of 1MED Group, she leads national and international studies across Europe, ensuring compliance, quality, and effective communication among sponsors, regulatory bodies, multiple vendors, and investigational sites.

Session Details:

Resilience by Design: A Proactive Operational Framework for Clinical Trial Management

2026-05-06, 9:30 AM

View In Agenda

Next speaker

Back

Maria João Marques, MSc, ACRP-CP

Senior Director for Clinical Solutions - Europe, Biorce

With over 15 years of international experience, Maria João Marques is a distinguished clinical research leader and a certified ACRP-CP professional. Her career is defined by a 360-degree perspective rooted in Clinical Academic Centers and R&D management, having held senior leadership roles across the UAE, the United Kingdom, Ireland and Portugal.

From her foundational roots in nursing to earning her Master’s in Leadership from Oxford Brookes University, Maria has remained dedicated to establishing patient-centered environments focused on compassion, evidence-based practice, and healthcare excellence. She is a specialist in building research infrastructures from the ground up, having pioneered the conception of world-class research departments internationally. Her work has been instrumental in establishing the complex governance, ethics, finance, and regulatory frameworks required to turn scientific vision into measurable impact. Maria has led high-impact R&D initiatives within the European quadruple helix, coordinating large-scale projects to capacitate institutions and promote high-quality clinical research.

As a certified Clinical Project Manager, Maria has transitioned from building traditional clinical facilities to leveraging the technology designed to redefine them. Now, as the Senior Director for Clinical Solutions in Europe at Biorce, she is deploying an AI platform built to eliminate manual bottlenecks and fundamentally transform clinical trial operations. Maria is passionate about bridging the gap between clinical evidence and AI-driven innovation to accelerate the delivery of meaningful health solutions globally.

Session Details:

AI-First Trials with Aika: How AI-Driven Operational Intelligence Is Changing Trial Execution

2026-05-06, 4:15 PM

View In Agenda

Next speaker

Back

Aida Perera Sánchez

Clinical Project Manager, Grupo Solti

Aida Perera Sánchez is a dynamic business professional dedicated to driving operational excellence and strategic growth. With a background in Clinical Research, she excels at managing complex projects and fostering collaborative team environments. Aida combines analytical thinking with a human-centric approach to leadership, ensuring that every project not only meets its KPIs but also contributes to a positive organizational culture.

Aida is a graduated a Master’s Degree in Clinical Trial monitoring and coordination and another Master in Project management from the Universidad Internacional de la Rioja

Session Details:

Small Decisions, Big Study Consequences

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Siobhan McKenna-Power

Operations Manager, 4G Clinical

Siobhan McKenna-Power has over 20 years of experience designing and delivering regulated systems, with over 10 years of experience in designing and delivering RTSM systems for clinical trials. She first developed an interest in clinical trials when her father took part in multiple Phase III drug and device trials due to his progressive chronic obstructive pulmonary disease.

Siobhan has a keen understanding of what the needs of the end user are and works to ensure that even the most complex trials are easy for Investigators to work with and that patient safety is the foremost priority of any RTSM system.

Siobhan is a graduate of Maynooth University (formerly National University of Ireland, Maynooth) with a BSc in Computer Science and Software Engineering. She is currently working on a Level 7 Diploma in Risk Management.

Session Details:

Small Decisions, Big Study Consequences

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Małgorzata Lorek

Study Project Lead III, 4G Clinical

Małgorzata Lorek, M.Sc.Eng., is an experienced clinical trial professional specializing in document and database management with a proven track record of delivering client-facing support and complex issue resolution. Currently at 4G Clinical, specializing in RTSM (Randomization and Trial Supply Management) systems. With nearly two decades of experience at organizations like ICON Laboratory Services, she has developed deep expertise in study design, system validation, and departmental performance metrics. Małgorzata is recognized for her ability to solve complex technical issues and her commitment to delivering high-quality, compliant solutions for global clinical trials. Malgorzata holds an M.Sc.Eng. in Chemistry and brings a deep understanding of regulatory standards, including GxP, to every project.

Session Details:

Small Decisions, Big Study Consequences

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Back

Katarzyna (Kasia) Kalisiak, PhD

Associate Director, Caidya, RBQM Solutions Department

Session Details:

From First-in-Human to Global Trials: How Emerging Biotechs and Biopharmas Can De-Risk Clinical Development

2026-05-07, 2:30 PM

View In Agenda

Next speaker

Back

Dr Julie Munch Khan

Chief Commercial Officer, Deallus

Julie is the Chief Commercial Office at Deallus, a market leading strategy consultancy, which was acquired by Global Data at the beginning of the year. Julie's career in life sciences spans 20 years with a focus on partnering with clients on strategy development on local, regional and global level . For more than decade Julie has led large global and regional competitive mindset training programmes for large pharma. Since 2017 Julie has regularly been engaged as an inspirational speaker on Competitive Mindset across brand, portfolio and corporate audiences. Her expertise includes clinical and commercial planning, brand & portfolio strategy as well as advising organisation on personalised healthcare approaches across various disease areas. Julie holds a PhD in Neuroscience from Imperial College London sponsored by Pfizer.

Next speaker

Back

Scott Davis

Vice President Clinical Services Europe, Novotech

Session Details:

Executing Modern Clinical Trials Across Europe: Challenges And Opportunities

2026-05-06, 12:00 PM

View In Agenda

Next speaker

Back

Jaume Costa

Clinical Trial and Monitoring Manager, SOLTI - Cancer Research

Jaume Costa is a clinical research professional specializing in oncology trials, with extensive experience in clinical operations and monitoring leadership. As Clinical Trial and Monitoring Manager at SOLTI, he oversees resource planning, team allocation, and the quality and consistency of monitoring activities across the organization’s clinical portfolio. He also leads initiatives focused on process optimization, training, and systems improvement to strengthen operational excellence and support high-quality clinical research.

Session Details:

Who Should Own Your eClinical Systems? Sponsor vs CRO Decisions That Actually Impact Trial Success

2026-05-06, 2:45 PM

View In Agenda

Next speaker

Advisory Board

Select a member to learn more

Back

Dr Alison McMorn

Head of Clinical Strategy and Development, LifeArc

Dr. McMorn is an experienced clinical development researcher with over 25 years of industry experience and has a strong focus in CNS and paediatric drug development. She has worked for both Pharmaceutical Companies and Contract Research Organisations including holding positions at SAR Monitoring Services Ltd, Mundipharma International Ltd and Shire Development Inc. Starting her career at SAR as a Clinical Research Associate (CRA) she subsequently moved to Mundipharma where she was responsible for initiating the first paediatric clinical research program for the company. At Shire Dr. McMorn led, planned and managed global paediatric and adult clinical development programs for a wide variety of indications including psychiatry, pain, gastrointestinal and hepatology across all phases of development (Phase 0 to Phase 4). In addition she was responsible for harmonizing Clinical Trial Administrator (CTA) working practices across all regions for the company. In 2015 Dr. McMorn joined AMO Pharma Ltd, a virtual pharmaceutical company focused predominantly on paediatric neurodevelopmental rare diseases, as VP of Clinical Development. She holds an undergraduate degree in Pharmacology and a PhD in Psychology from the University of Leeds, UK.

Back

Behtash Bahador

Senior Director, Community Engagement & Partnerships, CISCRP

Session Details:

CISCRP Perceptions & Insights Case Study

2026-05-07, 10:00 AM

Session Details:

ROUNDTABLE DISCUSSIONS

2026-05-07, 4:00 PM

View In Agenda

Back

Kathleen Cohen

Vice President, Clinical Development, Marinus Pharmaceuticals

Kathleen Frenia Cohen is Vice President and Head of Clinical Development Operations at Marinus Pharmaceuticals. Prior to joining Marinus, she spent 20+ years at PRA Health Sciences in a variety of project management and operational oversite roles. Kathleen graduated from the University of the Science in Philadelphia with a PharmD and completed a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research from Rutgers College of Pharmacy. Kathleen resides in Media, PA.

Back

Aditya Kotta

VP Business Development, Novotech

Aditya Kotta is the VP of Business Development for Novotech. He has been with the company since 2018. He has 14 years of experience in the clinical trial industry, working in both Clinical Operations and Business Development. He holds degrees in Biomedical Engineering from Johns Hopkins University and Medical Science from Boston University.

Back

Martin Rodriguez

Consumer Safety & Evidence Global Quality & Excellence Head, Opella

Senior executive Leader in Life Science (Biochemist) and Lean/Six Sigma Green-belt certified, with more than 20 year of experience in clinical operations, Operational Excellence (i.e., operational strategy, performance management, process optimization, risk management, Quality-by-Design and team performance), clinical quality, and Service Providers / Outsourcing management.

I developed, reengineered, automated, and optimized business processes with a risk-based and approach to produce high quality outputs and to ensure regulatory compliance. I led the development, implementation and monitoring of different operational and quality strategies and models including Outsourcing as well as new/ innovative clinical capabilities to fulfill consumers/ patients needs .

Back

Rosie Filling

Vice President, Senior Global Head R&D Operations, Endo

Back

Edwin van Vulpen

Executive Director and Head of Clinical Business Development Euro-Asia

Plan Your Visit

Venue

Hyatt Regency Barcelona Tower

Avinguda de la Granvia de l’Hospitalet, 144 Barcelona, 08907 Spain

Book Your Stay

Accommodation

Arena International Events Group “(Arena”) is aware of numerous third party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings and events attendee lists. For the avoidance of doubt, Arena will only share attendee lists with carefully selected third party partners for event registration purposes. Whilst Arena International Events Group pursues third party agencies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group.

2026 Sponsors

Select a sponsor to learn more

FEATURED SPONSORS

SESSION SPONSORS

Company Information

Ergomed has supported and managed clinical development, trial management, pharmacovigilance, and medical information services for over 300 clients in more than 100 countries.

We deliver a complete solution for oncology trials of all sizes and complexity. For more information about Ergomed, please visit: www.ergomedcro.com

Company Website

To learn more, please visit our website - www.ergomedcro.com

TECHNOLOGY SHOWCASE SPONSORS

Prize Draw Sponsor

LANYARD SPONSOR

Drinks Reception Sponsor

Pre-Conference Workshop Partner

Pens & Notepad Sponsor

Networking Zone & Badge Sponsor

Company Information

Company Website

To learn more, please visit our website - http://www.marken.com/

EXHIBITORS

Company Information

Advanthera is a Clinical Trial Services partner for pharma and biotechs, with strong focus on Advances Therapies. We foster innovation through collaboration, ensuring hight-quality, comprehensive support from start to finish providing expert services in clinical trials logistics, from preclinical to Phase III.
We do support a comprehensive Clinical Study Management through or Project Managers, which brings the full coordination of activities from operational to regulatory, including strategic supply planning for medication sourcing and fast-track study initiation.
Our facility capabilities includes storage at any range (15–25°C / 2–8°C / –20°C / –86°C), Biorepository area, including -20ºC, -80ºC and 196ºC (LN2 vapour phase) equipment. GMP area with four clean rooms, one running at 2-8ºC.
MIA (GMP certified including ATMPs), wholesaler licencse and GDP certifications, along with GMOs authorization allow us to be a one-stop solution for client needs.• GMP & QP Services – batch certification/QP release, documentation review, adaptation to EU standards including vendor audits, translation services, Packaging & Labeling – kit design and onsite GMP label printing. Electronic BR offering 100% traceability ensurig blinding through QR reading.
Global Distribution & Cold Chain Logistics, IMP/EXPO management, global depot network with qualified partners
Comparator & Ancillary – global sourcing strategies, pedigree management, direct from manufacturer options
Advanced Therapies (ATMP)– our Regulatory experts offers support during the development process with Technical Strategy on CMC and product characterization, Quality Assurance, and Regulatory Bodies submissions

Company Information

Company Website

To learn more, please visit our website - http://www.marken.com/

Co-Sponsor

Event Partners

Why partner?

Contact us to become a partner

Partnership Opportunities

We work with you to design a bespoke package to meet your business needs, where you could:

Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

Event reach

500+ attendees each year
80% attendees C-suite level

Take a look at our current sponsors

Resources

Media Centre

Become a media partner

A fantastic network of your peers and colleagues!

See What It's All About

Enquiry

Contact Us

SPONSORSHIP ENQUIRIES

Ben Lloyd-Davies

Commercial Director - Healthcare Events

benlloyd-davies@arena-international.com +61 280 978 126

SPEAKER ENQUIRIES

Maya Hudson

Head of Production

maya.hudson@arena-international.com +44 (0) 204 540 7766

MARKETING ENQUIRIES

Hattie Dean

Marketing Manager

hattie.dean@arena-international.com

DELEGATE ENQUIRIES

Sunny Saikia

VIP Delegate Manager

sunny.saikia@arena-international.com

Sponsorship Enquiries

To enquire about sponsorship opportunities for the conference, please contact:

Ben Lloyd-Davies

Commercial Director - Healthcare Events

BenLloyd-Davies@arena-international.com

+44 207 8669 497

Speaker Enquiries

To enquire about speaking opportunities for the conference, please contact:

Maya Hudson

Head of Production

maya.hudson@arena-international.com

+44 (0) 204 540 7766

17th Annual Outsourcing in Clinical Trials Europe 2027

Creating a collaborative environment where pharma & biotech leaders can find solutions to current challenges through innovations and partnerships

Featured Speakers

Ken Getz​

Bernhard Glombitza​

Emma Blasi Bosch​

Karin Nordbladh​

Piotr Maslak​

Kamil Sitarz, PhD, EMBA​

2026 Sponsors Include:

Why attend?

WHAT TO EXPECT FOR 2027?

Testimonials

See What It's All About

Agenda

Streams

11:30 AM

CASE STUDY: From Bench to Bedside: Building an End-to-End Biotech with an In-House Clinical Trial Unit

Speakers

12 PM

The Global biotech sector: A CRO perspective Insights from global and China biotech leaders – What sets winning companies apart

Speakers

12:30 PM

Choosing the right CRO: key considerations for small biotech’s

Speakers

1 PM

Lunch and networking

2 PM

PANEL DISCUSSION The biotech landscape in Europe 2026: growths, shifts and strategic outlook

Speakers

2:45 PM

Built for Biotech: A Fit for Purpose FSP Model That Scales with Innovation

Speakers

3:15 PM

The Pursuit of Success: Driving your drug from the lab to the patient

Speakers

3:45 PM

Afternoon refreshments and networking

4:15 PM

Reframing the CRO: From Vendor to Risk-Reduction Partner

Speakers

4:45 PM

Navigating the Evolving Biosimilars Landscape: Application of new FDA and EMA Guidance as illustrated with a biosimilar case study and implications for CROs

Speakers

5:30 PM

Chairs closing remarks and Drinks Reception

11:30 AM

Great expectations and how to meet them – Implementing AI into your study

Speakers

12 PM

Executing Modern Clinical Trials Across Europe: Challenges And Opportunities

Speakers

12:30 PM

FIESDIE CHAT From Machine Insight to Manuel Review: AI for Vendor Proposals We will focus on

Speakers

1 PM

Lunch and networking

2 PM

Superhuman Sourcing: The AI Evolution of Clinical Outsourcing

Speakers

2:15 PM

150 Days to Activation: What the UK’s New Trial Start-Up Standard Means for Europe

Speakers

2:45 PM

Who Should Own Your eClinical Systems? Sponsor vs CRO Decisions That Actually Impact Trial Success

Speakers

3:15 PM

Unlocking Efficiency in ClinicalTrials: Scaling eSource for Enhanced Data Management and Collaboration

Speakers

3:45 PM

Afternoon refreshments and networking

4:15 PM

AI-First Trials with Aika: How AI-Driven Operational Intelligence Is Changing Trial Execution

Speakers

4:45 PM

AI & SUSTAINABILITY SPOTLIGHT: From Consent to Carbon Footprint: Leveraging AI for Sustainable Bio sample Operations and Biobanks

Speakers

5:30 PM

Chairs closing remarks and Drinks Reception Sponsored by XXX

8 AM

Ken Getz

Bernhard Glombitza

Emma Blasi Bosch

Karin Nordbladh

Piotr Maslak

Kamil Sitarz, PhD, EMBA